Are 0 3 0 3 B-pregnancy
pregnant 4 12 4 12 I-pregnancy

Be 0 2 13 15 O
in 3 5 16 18 O
first 6 11 19 24 O
relapse 12 19 25 32 O
( 20 21 33 34 O
within 21 27 34 40 O
24 28 30 41 43 B-upper_bound
months 31 37 44 50 I-upper_bound
of 38 40 51 53 O
CR 41 43 54 56 B-treatment
) 43 44 56 57 O
or 45 47 58 60 O
have 48 52 61 65 O
failed 53 59 66 72 O
induction 60 69 73 82 B-treatment
therapy 70 77 83 90 I-treatment
* 77 78 90 91 O
( 79 80 92 93 O
no 80 82 93 95 O
CR 83 85 96 98 O
or 86 88 99 101 O
CRi 89 92 102 105 B-treatment
after 93 98 106 111 O
treatment 99 108 112 121 B-treatment
with 109 113 122 126 I-treatment
an 114 116 127 129 I-treatment
intensive 117 126 130 139 I-treatment
regimen 127 134 140 147 I-treatment
( 135 136 148 149 O
eg 136 138 149 151 O
, 138 139 151 152 O
anthracycline 140 153 153 166 B-treatment
/ 153 154 166 167 O
cytarabine 154 164 167 177 B-treatment
± 165 166 178 179 O
etoposide 167 176 180 189 B-treatment
, 176 177 189 190 O
gemtuzumab 178 188 191 201 O
ozogamicin 189 199 202 212 O
, 199 200 212 213 O
or 201 203 214 216 O
cladribine 204 214 217 227 O
) 214 215 227 228 O

Be 0 2 229 231 O
nonfertile 3 13 232 242 O
or 14 16 243 245 O
agree 17 22 246 251 B-contraception_consent
to 23 25 252 254 I-contraception_consent
use 26 29 255 258 I-contraception_consent
an 30 32 259 261 I-contraception_consent
adequate 33 41 262 270 I-contraception_consent
method 42 48 271 277 I-contraception_consent
of 49 51 278 280 I-contraception_consent
contraception 52 65 281 294 I-contraception_consent
. 65 66 294 295 O
Sexually 67 75 296 304 O
active 76 82 305 311 O
patients 83 91 312 320 O
and 92 95 321 324 O
their 96 101 325 330 O
partners 102 110 331 339 O
must 111 115 340 344 O
use 116 119 345 348 B-contraception_consent
an 120 122 349 351 I-contraception_consent
effective 123 132 352 361 I-contraception_consent
method 133 139 362 368 I-contraception_consent
of 140 142 369 371 I-contraception_consent
contraception 143 156 372 385 I-contraception_consent
associated 157 167 386 396 O
with 168 172 397 401 O
a 173 174 402 403 O
low 175 178 404 407 O
failure 179 186 408 415 O
rate 187 191 416 420 O
prior 192 197 421 426 O
to 198 200 427 429 O
study 201 206 430 435 O
entry 207 212 436 441 O
, 212 213 441 442 O
for 214 217 443 446 O
the 218 221 447 450 O
duration 222 230 451 459 O
of 231 233 460 462 O
study 234 239 463 468 O
participation 240 253 469 482 O
, 253 254 482 483 O
and 255 258 484 487 O
for 259 262 488 491 O
at 263 265 492 494 O
least 266 271 495 500 O
3 272 273 501 502 B-lower_bound
months 274 280 503 509 I-lower_bound
( 281 282 510 511 O
males 282 287 511 516 B-gender
) 287 288 516 517 O
and 289 292 518 521 O
6 293 294 522 523 B-lower_bound
months 295 301 524 530 I-lower_bound
( 302 303 531 532 O
females 303 310 532 539 B-gender
) 310 311 539 540 O
after 312 317 541 546 O
the 318 321 547 550 O
last 322 326 551 555 O
dose 327 331 556 560 O
of 332 334 561 563 O
study 335 340 564 569 B-treatment
drug 341 345 570 574 I-treatment

Demonstrate 0 11 575 586 O
MCL-1 12 17 587 592 B-clinical_variable
dependence 18 28 593 603 O
of 29 31 604 606 O
≥40 32 35 607 610 O
% 35 36 610 611 I-lower_bound
by 37 39 612 614 O
mitochondrial 40 53 615 628 O
profiling 54 63 629 638 O
in 64 66 639 641 O
bone 67 71 642 646 O
marrow 72 78 647 653 O

Diagnosed 0 9 654 663 O
with 10 14 664 668 O
acute 15 20 669 674 B-cancer
promyelocytic 21 34 675 688 I-cancer
leukemia 35 43 689 697 I-cancer
( 44 45 698 699 I-cancer
APL 45 48 699 702 I-cancer
, 48 49 702 703 I-cancer
M3 50 52 704 706 I-cancer
) 52 53 706 707 I-cancer

Have 0 4 708 712 O
a 5 6 713 714 O
left 7 11 715 719 B-clinical_variable
ventricular 12 23 720 731 I-clinical_variable
ejection 24 32 732 740 I-clinical_variable
fraction 33 41 741 749 I-clinical_variable
( 42 43 750 751 I-clinical_variable
LVEF 43 47 751 755 I-clinical_variable
) 47 48 755 756 I-clinical_variable
> 49 50 757 758 O
45 50 52 758 760 B-lower_bound
% 52 53 760 761 I-lower_bound
by 54 56 762 764 O
echocardiogram 57 71 765 779 B-treatment
( 72 73 780 781 I-treatment
ECHO 73 77 781 785 I-treatment
) 77 78 785 786 I-treatment
or 79 81 787 789 O
multigated 82 92 790 800 B-treatment
acquisition 93 104 801 812 I-treatment
( 105 106 813 814 I-treatment
MUGA 106 110 814 818 I-treatment
) 110 111 818 819 I-treatment
scan 112 116 820 824 I-treatment

Have 0 4 825 829 O
a 5 6 830 831 O
peripheral 7 17 832 842 B-clinical_variable
blast 18 23 843 848 I-clinical_variable
count 24 29 849 854 I-clinical_variable
of 30 32 855 857 O
> 33 34 858 859 O
30,000 34 40 859 865 B-lower_bound
/ 40 41 865 866 I-lower_bound
mm3 41 44 866 869 I-lower_bound
( 45 46 870 871 O
may 46 49 871 874 O
use 50 53 875 878 O
hydroxyurea 54 65 879 890 B-treatment
as 66 68 891 893 O
in 69 71 894 896 O
# 72 73 897 898 O
5 73 74 898 899 O
above 75 80 900 905 O
) 80 81 905 906 O

Have 0 4 907 911 O
a 5 6 912 913 O
serum 7 12 914 919 B-clinical_variable
creatinine 13 23 920 930 I-clinical_variable
level 24 29 931 936 I-clinical_variable
≤1.8 30 34 937 941 O
mg 35 37 942 944 I-upper_bound
/ 37 38 944 945 I-upper_bound
dL 38 40 945 947 I-upper_bound

Have 0 4 948 952 O
a 5 6 953 954 O
total 7 12 955 960 B-clinical_variable
bilirubin 13 22 961 970 I-clinical_variable
level 23 28 971 976 O
≤2.0 29 33 977 981 B-upper_bound
mg 34 36 982 984 I-upper_bound
/ 36 37 984 985 I-upper_bound
dL 37 39 985 987 I-upper_bound
( 40 41 988 989 O
unless 41 47 989 995 O
secondary 48 57 996 1005 O
to 58 60 1006 1008 O
Gilbert 61 68 1009 1016 B-chronic_disease
syndrome 69 77 1017 1025 I-chronic_disease
, 77 78 1025 1026 O
hemolysis 79 88 1027 1036 B-chronic_disease
, 88 89 1036 1037 O
or 90 92 1038 1040 O
leukemia 93 101 1041 1049 B-cancer
) 101 102 1049 1050 O

Have 0 4 1051 1055 O
active 5 11 1056 1062 O
central 12 19 1063 1070 B-cancer
nervous 20 27 1071 1078 I-cancer
system 28 34 1079 1085 I-cancer
( 35 36 1086 1087 I-cancer
CNS 36 39 1087 1090 I-cancer
) 39 40 1090 1091 I-cancer
leukemia 41 49 1092 1100 I-cancer

Have 0 4 1101 1105 O
an 5 7 1106 1108 O
Eastern 8 15 1109 1116 B-clinical_variable
Cooperative 16 27 1117 1128 I-clinical_variable
Oncology 28 36 1129 1137 I-clinical_variable
Group 37 42 1138 1143 I-clinical_variable
( 43 44 1144 1145 I-clinical_variable
ECOG 44 48 1145 1149 I-clinical_variable
) 48 49 1149 1150 I-clinical_variable
performance 50 61 1151 1162 I-clinical_variable
status 62 68 1163 1169 I-clinical_variable
( 69 70 1170 1171 I-clinical_variable
PS 70 72 1171 1173 I-clinical_variable
) 72 73 1173 1174 I-clinical_variable
≤2 74 76 1175 1177 O

Have 0 4 1178 1182 O
an 5 7 1183 1185 O
active 8 14 1186 1192 O
, 14 15 1192 1193 O
uncontrolled 16 28 1194 1206 O
infection 29 38 1207 1216 B-chronic_disease

Have 0 4 1217 1221 O
an 5 7 1222 1224 O
alanine 8 15 1225 1232 B-clinical_variable
aminotransferase 16 32 1233 1249 I-clinical_variable
( 33 34 1250 1251 I-clinical_variable
ALT)/aspartate 34 48 1251 1265 I-clinical_variable
aminotransferase 49 65 1266 1282 I-clinical_variable
( 66 67 1283 1284 I-clinical_variable
AST 67 70 1284 1287 I-clinical_variable
) 70 71 1287 1288 I-clinical_variable
level 72 77 1289 1294 I-clinical_variable
≤5 78 80 1295 1297 O
times 81 86 1298 1303 I-upper_bound
upper 87 92 1304 1309 I-upper_bound
limit 93 98 1310 1315 I-upper_bound
of 99 101 1316 1318 I-upper_bound
normal 102 108 1319 1325 I-upper_bound
( 109 110 1326 1327 I-upper_bound
ULN 110 113 1327 1330 I-upper_bound
) 113 114 1330 1331 I-upper_bound

Have 0 4 1332 1336 O
an 5 7 1337 1339 O
established 8 19 1340 1351 O
, 19 20 1351 1352 O
pathologically 21 35 1353 1367 O
confirmed 36 45 1368 1377 O
diagnoses 46 55 1378 1387 O
of 56 58 1388 1390 O
AML 59 62 1391 1394 B-clinical_variable
by 63 65 1395 1397 O
World 66 71 1398 1403 O
Health 72 78 1404 1410 O
Organization 79 91 1411 1423 O
( 92 93 1424 1425 O
WHO 93 96 1425 1428 O
) 96 97 1428 1429 O
criteria 98 106 1430 1438 O
excluding 107 116 1439 1448 O
acute 117 122 1449 1454 B-cancer
promyelocytic 123 136 1455 1468 I-cancer
leukemia 137 145 1469 1477 I-cancer
( 146 147 1478 1479 I-cancer
APL 147 150 1479 1482 I-cancer
- 150 151 1482 1483 I-cancer
M3 151 153 1483 1485 I-cancer
) 153 154 1485 1486 I-cancer
with 155 159 1487 1491 O
a 160 161 1492 1493 O
bone 162 166 1494 1498 O
marrow 167 173 1499 1505 O
of 174 176 1506 1508 O
> 177 178 1509 1510 O
5 178 179 1510 1511 B-lower_bound
% 179 180 1511 1512 I-lower_bound
blasts 181 187 1513 1519 O
based 188 193 1520 1525 O
on 194 196 1526 1528 O
histology 197 206 1529 1538 O
or 207 209 1539 1541 O
flow 210 214 1542 1546 O
cytometry 215 224 1547 1556 O

Have 0 4 1557 1561 O
clinically 5 15 1562 1572 O
significant 16 27 1573 1584 O
graft 28 33 1585 1590 B-chronic_disease
versus 34 40 1591 1597 I-chronic_disease
host 41 45 1598 1602 I-chronic_disease
disease 46 53 1603 1610 I-chronic_disease
( 54 55 1611 1612 I-chronic_disease
GVHD 55 59 1612 1616 I-chronic_disease
) 59 60 1616 1617 I-chronic_disease
, 60 61 1617 1618 O
or 62 64 1619 1621 O
GVHD 65 69 1622 1626 O
requiring 70 79 1627 1636 O
initiation 80 90 1637 1647 O
or 91 93 1648 1650 O
escalation 94 104 1651 1661 O
of 105 107 1662 1664 O
treatment 108 117 1665 1674 B-treatment
within 118 124 1675 1681 O
the 125 128 1682 1685 O
last 129 133 1686 1690 B-upper_bound
21 134 136 1691 1693 I-upper_bound
days 137 141 1694 1698 I-upper_bound

Have 0 4 1699 1703 O
evidence 5 13 1704 1712 O
of 14 16 1713 1715 O
uncontrolled 17 29 1716 1728 O
disseminated 30 42 1729 1741 B-chronic_disease
intravascular 43 56 1742 1755 I-chronic_disease
coagulation 57 68 1756 1767 I-chronic_disease

Have 0 4 1768 1772 O
mental 5 11 1773 1779 B-chronic_disease
deficits 12 20 1780 1788 I-chronic_disease
and/or 21 27 1789 1795 O
psychiatric 28 39 1796 1807 B-chronic_disease
history 40 47 1808 1815 O
that 48 52 1816 1820 O
may 53 56 1821 1824 O
compromise 57 67 1825 1835 O
the 68 71 1836 1839 O
ability 72 79 1840 1847 O
to 80 82 1848 1850 O
give 83 87 1851 1855 O
written 88 95 1856 1863 O
informed 96 104 1864 1872 O
consent 105 112 1873 1880 O
or 113 115 1881 1883 O
to 116 118 1884 1886 O
comply 119 125 1887 1893 O
with 126 130 1894 1898 O
the 131 134 1899 1902 O
study 135 140 1903 1908 O
protocol 141 149 1909 1917 O

Have 0 4 1918 1922 O
other 5 10 1923 1928 O
active 11 17 1929 1935 O
malignancies 18 30 1936 1948 B-cancer
or 31 33 1949 1951 O
diagnosed 34 43 1952 1961 O
with 44 48 1962 1966 O
other 49 54 1967 1972 O
malignancies 55 67 1973 1985 O
within 68 74 1986 1992 O
the 75 78 1993 1996 O
last 79 83 1997 2001 B-upper_bound
6 84 85 2002 2003 I-upper_bound
months 86 92 2004 2010 I-upper_bound
, 92 93 2010 2011 O
except 94 100 2012 2018 O
nonmelanoma 101 112 2019 2030 B-cancer
skin 113 117 2031 2035 I-cancer
cancer 118 124 2036 2042 I-cancer
or 125 127 2043 2045 O
cervical 128 136 2046 2054 B-cancer
intraepithelial 137 152 2055 2070 I-cancer
neoplasia 153 162 2071 2080 I-cancer

Have 0 4 2081 2085 O
received 5 13 2086 2094 O
any 14 17 2095 2098 O
live 18 22 2099 2103 B-treatment
vaccine 23 30 2104 2111 I-treatment
within 31 37 2112 2118 O
14 38 40 2119 2121 B-upper_bound
days 41 45 2122 2126 I-upper_bound
prior 46 51 2127 2132 I-upper_bound
to 52 54 2133 2135 O
first 55 60 2136 2141 O
study 61 66 2142 2147 B-treatment
drug 67 71 2148 2152 I-treatment
administration 72 86 2153 2167 O

Received 0 8 2168 2176 O
> 9 10 2177 2178 O
360 10 13 2178 2181 B-lower_bound
mg 14 16 2182 2184 I-lower_bound
/ 16 17 2184 2185 I-lower_bound
m2 17 19 2185 2187 I-lower_bound
equivalents 20 31 2188 2199 O
of 32 34 2200 2202 O
daunorubicin 35 47 2203 2215 B-treatment

Received 0 8 2216 2224 O
a 9 10 2225 2226 O
hematopoietic 11 24 2227 2240 B-treatment
stem 25 29 2241 2245 I-treatment
cell 30 34 2246 2250 I-treatment
transplant 35 45 2251 2261 I-treatment
within 46 52 2262 2268 O
the 53 56 2269 2272 O
previous 57 65 2273 2281 B-upper_bound
2 66 67 2282 2283 I-upper_bound
months 68 74 2284 2290 I-upper_bound

Received 0 8 2291 2299 O
antileukemic 9 21 2300 2312 B-treatment
therapy 22 29 2313 2320 I-treatment
within 30 36 2321 2327 O
the 37 40 2328 2331 O
last 41 45 2332 2336 B-upper_bound
3 46 47 2337 2338 I-upper_bound
weeks 48 53 2339 2344 I-upper_bound
( 54 55 2345 2346 O
with 55 59 2346 2350 O
the 60 63 2351 2354 O
exception 64 73 2355 2364 O
of 74 76 2365 2367 O
hydroxyurea 77 88 2368 2379 B-treatment
or 89 91 2380 2382 O
if 92 94 2383 2385 O
the 95 98 2386 2389 O
patient 99 106 2390 2397 O
has 107 110 2398 2401 O
definite 111 119 2402 2410 O
refractory 120 130 2411 2421 O
disease 131 138 2422 2429 O
) 138 139 2429 2430 O
. 139 140 2430 2431 O
Refractory 141 151 2432 2442 O
patients 152 160 2443 2451 O
who 161 164 2452 2455 O
received 165 173 2456 2464 O
therapy 174 181 2465 2472 O
within 182 188 2473 2479 O
the 189 192 2480 2483 O
last 193 197 2484 2488 O
3 198 199 2489 2490 O
weeks 200 205 2491 2496 O
may 206 209 2497 2500 O
be 210 212 2501 2503 O
eligible 213 221 2504 2512 O
with 222 226 2513 2517 O
prior 227 232 2518 2523 O
approval 233 241 2524 2532 O
of 242 244 2533 2535 O
the 245 248 2536 2539 O
Medical 249 256 2540 2547 O
Monitor 257 264 2548 2555 O

Received 0 8 2556 2564 O
any 9 12 2565 2568 O
previous 13 21 2569 2577 O
treatment 22 31 2578 2587 B-treatment
with 32 36 2588 2592 I-treatment
alvocidib 37 46 2593 2602 I-treatment
or 47 49 2603 2605 O
any 50 53 2606 2609 O
other 54 59 2610 2615 O
CDK 60 63 2616 2619 B-treatment
inhibitor 64 73 2620 2629 I-treatment

Received 0 8 2630 2638 O
more 9 13 2639 2643 O
than 14 18 2644 2648 O
2 19 20 2649 2650 B-lower_bound
cycles 21 27 2651 2657 I-lower_bound
of 28 30 2658 2660 O
induction 31 40 2661 2670 B-treatment
therapy 41 48 2671 2678 I-treatment
for 49 52 2679 2682 O
AML 53 56 2683 2686 B-cancer
. 56 57 2686 2687 O
Investigational 58 73 2688 2703 B-treatment
agents 74 80 2704 2710 I-treatment
as 81 83 2711 2713 O
part 84 88 2714 2718 O
of 89 91 2719 2721 O
front 92 97 2722 2727 B-treatment
- 97 98 2727 2728 I-treatment
line 98 102 2728 2732 I-treatment
therapy 103 110 2733 2740 I-treatment
for 111 114 2741 2744 O
AML 115 118 2745 2748 O
may 119 122 2749 2752 O
by 123 125 2753 2755 O
acceptable 126 136 2756 2766 O
following 137 146 2767 2776 O
discussion 147 157 2777 2787 O
with 158 162 2788 2792 O
the 163 166 2793 2796 O
Medical 167 174 2797 2804 O
Monitor 175 182 2805 2812 O
. 182 183 2812 2813 O
Hydroxyurea 184 195 2814 2825 B-treatment
is 196 198 2826 2828 O
permitted 199 208 2829 2838 O
( 209 210 2839 2840 O
see 210 213 2840 2843 O
# 214 215 2844 2845 O
5 215 216 2845 2846 O
below 217 222 2847 2852 O
) 222 223 2852 2853 O

Require 0 7 2854 2861 O
concomitant 8 19 2862 2873 B-treatment
chemotherapy 20 32 2874 2886 I-treatment
, 32 33 2886 2887 O
radiation 34 43 2888 2897 B-treatment
therapy 44 51 2898 2905 I-treatment
, 51 52 2905 2906 O
or 53 55 2907 2909 O
immunotherapy 56 69 2910 2923 B-treatment
. 69 70 2923 2924 O
Hydroxyurea 71 82 2925 2936 B-treatment
is 83 85 2937 2939 O
allowed 86 93 2940 2947 O
up 94 96 2948 2950 O
to 97 99 2951 2953 O
the 100 103 2954 2957 O
evening 104 111 2958 2965 O
before 112 118 2966 2972 O
starting 119 127 2973 2981 O
( 128 129 2982 2983 O
but 129 132 2983 2986 O
not 133 136 2987 2990 O
within 137 143 2991 2997 O
12 144 146 2998 3000 B-upper_bound
hours 147 152 3001 3006 I-upper_bound
) 152 153 3006 3007 O
of 154 156 3008 3010 O
starting 157 165 3011 3019 O
treatment 166 175 3020 3029 B-treatment
on 176 178 3030 3032 O
either 179 185 3033 3039 O
arm 186 189 3040 3043 O

between 0 7 3044 3051 O
the 8 11 3052 3055 O
ages 12 16 3056 3060 B-age
of 17 19 3061 3063 O
≥18 20 23 3064 3067 O
and 24 27 3068 3071 O
≤65 28 31 3072 3075 O
years 32 37 3076 3081 I-upper_bound

